Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal
reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once
daily during four-week treatment with an extension treatment for non-responding patients. The
study includes a baseline period up to 14 days and a treatment period of either 4 weeks (28
-2 + 5 days), or 8 weeks depending on the cure of esophagitis due to gastroesophageal reflux.
The study will provide further data on safety and tolerability of pantoprazole magnesium.